Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Via News Knowledge File

Pfizer Inc.

organization80% conf.·synced Aug 16, 2026

Pharmaceutical company, collaboration partner on Padcev

53
sourced metrics
660
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Field Force Ranking
1rank
source
Stock Return Ytd
6.4%
Aug 14, 2026reference only
Price 52 Week High
28.55USD
Aug 14, 2026reference only
Market Cap
152694255449USD
Aug 14, 2026reference only
Stock Price
26.79USD
Aug 14, 2026reference only
Price 52 Week Low
23.60USD
Aug 14, 2026reference only
Shares Outstanding
5699673589.0shares
Jul 29, 2026reference only
Cash
976000000.0USD
Jun 28, 2026reference only
Total Liabilities
115639000000.0USD
Jun 28, 2026reference only
Total Assets
201131000000.0USD
Jun 28, 2026reference only
Cost Of Revenue
4092000000.0USD
Jun 28, 2026reference only
Stockholders Equity
85190000000.0USD
Jun 28, 2026reference only
Eps
-0.04USD_per_share
Jun 28, 2026reference only
Revenue
15034000000.0USD
Jun 28, 2026reference only
Net Income
-248000000.0USD
Jun 28, 2026reference only
Discovery Programs Contributed To Collaboration
4programs
May 28, 2026source
Collaboration Program Count
12programs
May 28, 2026source
Late Breaking Sessions
3sessions
Apr 21, 2026source

Stated objectives

Enhance global ADC access through acquisition of Seagen

source
stated

Obtain regulatory approval for HYMPAVZI for treatment of hemophilia A or B with inhibitors from FDA and EMA

source
stated

Complete BASIS KIDS study to evaluate safety and efficacy of HYMPAVZI in children up to <18 years with hemophilia A or B with or without inhibitors

source
stated

Evaluate long-term safety and efficacy of HYMPAVZI in hemophilia patients with or without inhibitors in ongoing open-label long-term extension study

source
stated

Achieve revenues between $59.5 billion and $62.5 billion in 2026

source
target: 59.5-62.5 billion USD by 2026-12-31 00:00:00stated

Achieve adjusted EPS between $2.80 and $3 per share in 2026

source
target: 2.80-3.00 USD by 2026-12-31 00:00:00stated

Establish BRAFTOVI as standard of care for BRAF V600E-mutant metastatic colorectal cancer

source
stated

Pfizer 2026 revenue guidance midpoint

source
target: $61B by 2026-12-31 00:00:00stated

Pfizer 2026 EPS guidance midpoint

source
target: $2.90 by 2026-12-31 00:00:00stated

Expand HYMPAVZI indication to include hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients ages 6 to 11 without inhibitors

source
target: FDA approval stated

Relationship graph · 660 connections

Developed by
209
Competes with
78
acquired by
40
Covered by
35
regulates
32
Partnered with
28
Employs
23
Supplies to
21

Via News coverage

European Pharma in Flux: Orion Bets on R&D Growth as Global Restructuring Reshapes EU Drug Pipelines
February 18, 2026
IDEX BIOMETRICS And KERING On The List Of Winners And Losers Of Wednesday's Euronext Session
March 20, 2024
LHYFE And BIOSENIC On The List Of Winners And Losers Of Tuesday's Euronext Session
March 19, 2024
ARCHER And SAS AB On The List Of Winners And Losers Of Friday's Euronext Session
March 8, 2024
SOLVAY, MULTICONSULT, Another 4 Companies Have A High Estimated Dividend Yield
February 24, 2024
ENSURGE MICROPOWER And PROACTIS SA On The List Of Winners And Losers Of Tuesday's Euronext Session
February 20, 2024
EURO RESSOURCES, TOUR EIFFEL, Another 7 Companies Have A High Estimated Dividend Yield
February 18, 2024
SAGA PURE, TIETOEVRY, Another 6 Companies Have A High Estimated Dividend Yield
February 15, 2024
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →